Chinese scientists isolated Ebola antibodies

Separating future from immune macaques or treating infected people

　　 Recently, the State Key Laboratory of Respiratory Diseases jointly established by the Guangzhou Institute of Biomedicine and Health and the Guangzhou Medical University of the Chinese Academy of Sciences, in close cooperation with Tsinghua University and other units, has been able to fight against angstroms from immunized macaques through single cell cloning and other techniques. Efficient antibodies to the Bola virus may be used to treat patients and prevent Ebola infection in the future.

The study was published online May 17 in Scientific Reports on the topic of Potent neutralizing monoclonal antibodies against Ebola virus infection ("Efficient monoclonal neutralizing antibodies against Ebola virus infection"). Zhang Linqi, a professor at Tsinghua University, and Chen Ling, a researcher at the State Key Laboratory of Respiratory Diseases, and Qiu Xianguo, a professor at the Canadian Public Health Bureau, are co-authors of the article. Dr. Zhang Wei from Tsinghua University, Dr. Gui Yan from Tsinghua University, and Dr. Niu Xuefeng from the First Affiliated Hospital of Guangzhou Medical University were listed as the first authors of the article.

The team consisting of researchers from the Guangzhou Institute of Biomedicine and Health of the Chinese Academy of Sciences, Guangzhou Medical University, and Tsinghua University began to conduct research on Ebola virus in China from the early days of the prevalence of Ebola virus in West Africa in early 2014. jobs. In the end, the project research team successfully isolated three monoclonal antibodies with high and moderate humanized anti-Ebola virus from peripheral blood lymphocytes in immunized Chinese macaques; and with the Canadian Public Health Bureau Chinese Scientist Qiu Xiangguo cooperated to test the animal protection experiments of Ebola live virus, and proved that two of the antibodies played a strong "neutralization" effect after 48 hours of infection with Ebola virus.

In an interview with this newspaper, the researchers explained the "high-efficiency monoclonal neutralizing antibody": "highly efficient" means that the antibody works very well; "neutralization" refers to the "neutralization" of antibodies and viruses, Blocking the infection of the virus; and "monoclonal" refers to the expansion of the antibody after it has been extracted from a single cell. Due to the high degree of humanization of antibodies, after clinical safety studies, it can be used to treat Ebola patients.

Fight against more different types of viruses in the future

　　 Ebola viruses are also divided into different types. At present, the research team is carrying out the second generation of anti-Ebola monoclonal antibody research, through fixed-point gene mutation, structural and functional identification, multiple antigen immunization methods, looking for stronger neutralizing ability, can fight more different sub-Asia The antibodies and combinations of Ebola viruses are designed to optimize and protect Ebola's preventive and therapeutic antibodies, and to ensure greater national security and people's health .

The participating units of the project also include the Institute of Microbiology of the Chinese Academy of Sciences and the Collaborative Innovation Center for the Diagnosis and Treatment of Infectious Diseases . The research was supported by the National Natural Science Foundation of China and the Guangzhou Municipal Health and Medical Cooperative Innovation Project.

Background information: There are still no anti-Ai official drugs and vaccines

　　 The Ebola virus is one of the most deadly infectious viruses known to humans to date, with an average mortality rate of around 40%. Found in the Democratic Republic of the Congo in 1976, it has been a small outbreak and epidemic in Central African countries and regions. Beginning in the spring of 2014, the Ebola outbreak suddenly broke out in Guinea, Liberia and Sierra Leone in western Africa, causing a catastrophic blow to people's lives, economic development and social stability, and proposing public health and safety under the new situation. An unprecedented challenge.

Fundamentally curbing the outbreaks and epidemics of new infectious diseases such as Ebola depends on effective and accessible medical interventions. But so far, there are no clinically specific treatments and preventive vaccines for Ebola, and only a small number of countries such as Canada have produced experimental drugs and vaccines.